Bivalirudin lessens incidence of major bleeding in acute coronary syndromes
This article has no abstract so we have provided the first paragraph of the full text.
Patients with moderate-risk or high-risk acute coronary syndromes (ACS) benefit from an early invasive approach to treatment. Concomitant antithrombotic therapy is also recommended; however, rates of mortality and myocardial infarction remain high. Stone et al. have investigated the effects of concomitant treatment with bivalirudin, a synthetic thrombin-specific anticoagulant, and shown that it reduces the incidence of major bleeding events in patients who undergo early invasive treatment for ACS.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Thrombi?beware of red cells bearing giftsNature Biotechnology News and Views (01 Aug 2003)
Nucleotides and cd39: Principal modulatory players in hemostasis and thrombosisNature Medicine News and Views (01 Sep 1999)
